enasidenib for idh2-mutated mds
Published 4 years ago • 112 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
2:01
phase ii trial of enasidenib in idh2-mutant mds
-
2:34
the role of ezh2 mutations in mds
-
1:14
the impact of idh mutations in mds & evaluating the role of idh inhibitors
-
1:19
the next steps for the idh2 inhibitor drug enasidenib
-
1:18
beat aml master sub-study: enasidenib and response-driven addition of azacitidine in idh2m aml
-
1:32
idiome: ivosidenib in idh1 mutant mds
-
1:15
outcomes of non-intensive chemotherapy differ for idh1 and idh2-mutated aml
-
4:10
explore idh mutations
-
47:26
post ash22 mds summary
-
14:50
the effect of idh1 and idh2 mutations on the progression of glioblastoma
-
1:32
idh inhibitors for aml and mds
-
1:53
treatment strategies for patients with idh1/2-mutated aml ineligible for intensive chemotherapy
-
1:17
phase ii study of tosedostat in mds
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
1:48
overall survival by idh2 mutant allele in late-stage r/r aml patients enrolled in idhentify
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
1:51
idh1/2 inhibitors for upfront aml therapy and transfusion independence
-
7:18
phase i study shows ag-221 induces durable remissions in idh2-mutant acute myeloid leukaemia
-
2:05
does imetelstat increase the need for platelet transfusions & growth factors in pts with lr-mds?
-
9:41
the i4mds consortium and immune monitoring in mds
-
2:41
an overview of the latest advances in hematology